Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 20.87%. Currently, Vertex Pharmaceuticals
Unveiling 5 Analyst Insights On Editas Medicine
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent rating
Editas Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 125.56% Oppenheimer $12 → $12 Maintains Perform 05/30/2024 31.58% Evercore ISI Group $15 → $7 M
13 Analysts Have This To Say About Vertex Pharmaceuticals
Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary o
$100 Invested In Agilent Technologies 15 Years Ago Would Be Worth This Much Today
Agilent Technologies (NYSE:A) has outperformed the market over the past 15 years by 1.12% on an annualized basis producing an average annual return of 13.9%. Currently, Agilent Technologies has a mark
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) as her final trade.NVIDIA recently announced a 10-for-1 stock split. Th
CRISPR Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 38.36% Needham $88 → $88 Reiterates Buy → Buy 05/23/2024 32.08% Citigroup $89 → $84 Maintains B
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Avidity Biosciences, Inc. (NASDAQ:RNA) shares jumped 50.15% following the announcement that the Phase 1/2 tri
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusionPatients had early normalization of total hemoglobin with a mean within t
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Wall Street's Most Overbought Stocks Include NVDA, COST, LLY, and Others
Industry Comparison: Evaluating Agilent Technologies Against Competitors In Life Sciences Tools & Services Industry
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.JP Morgan s
Arcturus' Inhaled MRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Friday, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032, an inhaled investigation
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
On Thursday, Cathie Wood-led Ark Invest made significant trades in Amazon.com Inc (NASDAQ:AMZN) and Reddit Inc (NYSE:RDDT), amidst notable developments in both companies.The Amazon.com Trade: Ark Inve
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.91% on an annualized basis producing an average annual return of 22.94%. Currently, Vertex Pharmaceuticals h
Top 4 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go u
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics
In the last three months, 4 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), offering a diverse range of perspectives from bullish to bearish.The following table summarizes thei
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 179.93% Cantor Fitzgerald $65 → $65 Reiterates Overweight → Overweight 05/10/2024 24.89% Citigr
Looking Into Agilent Technologies's Recent Short Interest
Agilent Technologies's (NYSE:A) short percent of float has fallen 9.94% since its last report. The company recently reported that it has 4.24 million shares sold short, which is 1.63% of all regular s